Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia

Journal of Korean Medical Science

Volumn 23, Issue 5, 2008, Pages 833-837

  Bang, Soo Mee ^a   Jeong, Yeal Ahn ^b   Park, Jiyoon ^b   Se, Hoon Park ^b   Park, Jinny ^b   Eun, Kyung Cho ^b   Dong, Bok Shin ^b   Jae, Hoon Lee ^b   Soo, Jin Yoo ^c   In, Sang Jeon ^b   Kim, Yeo Kyeoung ^d   Hyeoung, Joon Kim ^d   Kim, Hee Nam ^e   Lee, Il Kwon ^e   Hyoung, Jin Kang ^f   Hee, Young Shin ^f   Hyo, Seop Ahn ^f  

^a Seoul National University Bundang Hospital   (South Korea)

^b Gachon University   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Chonnam National University Medical School   (South Korea)

^e Chonnam National University Research Institute of Medical Sciences   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

Author keywords

FLT3 mutations; Internal tandem duplication; Leukemia, myeloid, acute; Tyrosine kinase domain mutation

Indexed keywords

CD135 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFANT; KOREA; MALE; MIDDLE AGED; MUTATION; NEWBORN; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; REMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; INFANT, NEWBORN; KOREA; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RECURRENCE; REMISSION INDUCTION;

EID: 56049091809     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2008.23.5.833     Document Type: Article

References (32)

1. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-8.
2. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kahsima K, Matsuo Y, Naoe T. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodyplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997; 11: 1605-9.
3. Kiyoi H, Naoe T. FLT3 in human hematologic malignancies. Leuk Lymphoma 2002; 43: 1541-7.
4. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-9.
5. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001; 113: 983-8.
6. Spiekermann K, Bagrintseva K, Schoch C, Haferlach T, Hiddemann W, Schnittger S. A new recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood 2002; 100: 3423-5.
7. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650-65.
8. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, Illmer T. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-35.
9. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-80.
10. Boissel N, Cayuela JM, Preudhomme C, Thomas X, Grardel N, Fund X, Tigaud I, Raffoux E, Rousselot P, Sigaux F, Degos L, Castaigne S, Fenaux P, Dombret H. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002; 16: 1699-704.
11. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-9.
12. Kainz B, Heintel D, Marculescu R, Schwarzinger I, Sperr W, Le T, Weltermann A, Fonatsch C, Haas OA, Mannhalter C, Lechner K, Jaeger U. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematol J 2002; 3: 283-9.
13. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Loffler H, Sauerland CM, Serve H, Buchner T, Haferlach T, Hiddemann W. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
14. Kim YK, Lee JJ, Lee YR, Lee IK Kim HN, Kim NY, Park KS, Yang DH, Park MR, Kim HJ. The presence of FLT3/ITD mutations is an independent prognostic factor in acute myeloid leukemia patients with normal karyotype. Blood 2004; 104: 3008a.
15. Moreno I, Martin G, Bolufer P, Barragan E, Rueda E, Roman J, Fernandez P, Leon P, Mena A, Cervera J, Torres A, Sanz MA. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica 2003; 88: 19-24.
16. Kang HJ, Hong SH, Kim IH, Park BK, Han KS, Cho HI, Shin HY, Ahn HS. Prognostic significance of FLT3 mutations in pediatric nonpromyelocytic acute myeloid leukemia. Leuk Res 2005; 29: 617-23.
17. Nakano Y, Kiyoi H, Miyawaki S, Asou N, Ohno R, Saito H, Naoe T. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol 1999; 104: 659-64.
18. Mead A, Linch D, Hills R, Wheatley K, Burnett A, Gale R. Favourable prognosis associated with FLT3 tyrosine kinase domain mutations in AML in contrast to the adverse outcome associated with internal tandem duplications. Blood 2005; 106: 334a.
19. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN, Kuo MC, Lai CL, Hsu HC. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002; 100: 2387-92.
20. Hovland R, Gjertsen BT, Bruserud O. Acute myelogenous leukemia with internal tandem duplication of the Flt3 gene appearing or altering at the time of relapse: a report of two cases. Leuk Lymphoma 2002; 43: 2027-9.
21. Tiesmeier J, Muller-Tidow C, Westermann A, Czwalinna A, Hoffmann M, Krauter J, Heil G, Ganser A, Serve H, Verbeek W. Evolution Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy. Leuk Res 2004; 28: 1069-74.
22. Cloos J, Zwaan CM, Corthals SL, Goemans BF, Waisfisz Q, Creutzig U, Reinhardt D, Hahlen K, Kaspers GJL. FLT3/internal tandem duplication in paired presentation and relapse pediatric AML. Blood 2004; 102: 334a.
23. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood 1998; 92: 2322-33.
24. Wang L, Lin D, Zhang X, Chen S, Wang M, Wang J. Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients. Leuk Res 2005; 29: 1393-8.
25. Yoo SJ, Park CJ, Jang S, Seo EJ, Lee KH, Chi HS. Inferior prognostic outcome in acute promyelocytic leukemia with alteration of FLT3 gene. Leuk Lymphoma 2006; 47: 1788-93.
26. Kong SY, Ki CS, Lee SG, Hong SA, Kim JW, Kim SH. Analysis of FLT3-activiating mutations in 77 patients with acute myelogenous leukemia; association with WHO classification. Korean J Hematol 2003; 38: 44a.
27. Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hahlen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJ, Griesinger F. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 2003; 102: 2387-94.
28. Lacayo NJ, Meshinchi S, Raimondi SC, Kuo DJ, Yu R, Chang MN, Willman CL, Tibshirani R, Ravindranath Y, Sikic BI, Weinstein, Dahl GV. FLT3 mutations determine the clinical outcome in children with de novo acute myelogenous leukemia (AML) and normal karyotype: Pediatric Oncology Group (POG) Study # 9421. Blood 2004; 104: 570a.
29. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-83.
30. Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, Nugent E, Mills KI, Wheatley K, Solomon E, Burnett AK, Linch DC, Grimwade D. NCRI Adult Leukaemia Working Party. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 2005; 106: 3768-76.
31. Sternberg DW, Licht JD. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. Curr Opin Hematol 2005; 12: 7-13.
32. Kuchenbauer F, Schoch C, Kern W, Hiddemann W, Haferlach T, Schnittger S. Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. Br J Haematol 2005; 130: 196-202.